Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Invest Dermatol. 2011 Sep;131(9):1806-16. doi: 10.1038/jid.2011.160. Epub 2011 Jun 16.
T-cell receptor (TCR) gene therapy aims to induce immune reactivity against tumors by introducing genes encoding a tumor-reactive TCR into patient T cells. This approach has been extensively tested in preclinical mouse models, and initial clinical trials have demonstrated the feasibility and potential of TCR gene therapy as a cancer treatment. However, data obtained from preclinical and clinical studies suggest that both the therapeutic efficacy and the safety of TCR gene therapy can be and needs to be further enhanced. This review highlights those strategies that can be followed to develop TCR gene therapy into a clinically relevant treatment option for cancer patients.
T 细胞受体（TCR）基因治疗旨在通过将编码肿瘤反应性 TCR 的基因引入患者 T 细胞中来诱导针对肿瘤的免疫反应。这种方法已经在临床前小鼠模型中进行了广泛的测试，并且初步的临床试验已经证明了 TCR 基因治疗作为癌症治疗的可行性和潜力。然而，来自临床前和临床研究的数据表明，TCR 基因治疗的疗效和安全性都可以而且需要进一步提高。本综述强调了可以采用的那些策略，将 TCR 基因治疗开发成一种对癌症患者具有临床相关性的治疗选择。
